# Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut

Source: https://onco.cc/trials/nct07805954/  
OnCo record `nct07805954` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07805954 by Revolution Medicines, Inc., with 400 participants planned, started 2026-08-28 and due to reach its primary completion in 2029-03. Interventions recorded: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib. Conditions listed: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07805954
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT07805954: https://clinicaltrials.gov/study/NCT07805954

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct07805954.json